Infanrix Polio

Poliovirus (Inactivated) Type 3 (Saukett Strain) and Pertussis Filamentous Haemagglutinin, the active ingredients in Infanrix Polio, are a vaccine presented as an injectable formulation for intramuscular use. It induces protective immunity against poliovirus type 3 and pertussis in infants and children.

GNH USA supplies Infanrix Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global immunization programs, including cold‑chain logistics and comprehensive documentation for seamless distribution.

Infanrix Polio is used to prevent infections caused by poliovirus type 3 and pertussis, as part of routine childhood immunization. - Poliomyelitis (Polio): prevents poliomyelitis caused by poliovirus type 3. - Pertussis (Whooping Cough): prevents pertussis infection. - Diphtheria: provides immunity against diphtheria toxin. - Tetanus: provides protection against tetanus toxin.

Infanrix Polio may be associated with local and systemic reactions following injection.

Common Side Effects: - Injection site pain. - Redness at the injection site. - Swelling at the injection site. - Low‑grade fever. - Irritability. - Decreased appetite.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Seizure. - High fever. - Persistent crying. - Encephalopathy. - Guillain‑Barré syndrome.

Before administering Infanrix Polio, consider the following precautions. - Age restriction: not administered to infants under 6 weeks. - Previous allergic reaction: avoid if severe allergy to any vaccine component. - Immunocompromised patients: consult healthcare provider before vaccination. - Concurrent immunoglobulin therapy: may diminish vaccine efficacy. - Pregnancy: safety not established; weigh benefits and risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Infanrix Polio can interact with other therapies; review the following.

Major Interactions (Avoid): - Immunoglobulin or blood products administered within 4 weeks: may blunt vaccine efficacy. - Live viral vaccines given within 4 weeks: increased risk of adverse events. - Antipyretics taken before vaccination: may reduce immune response.

Moderate Interactions (Monitor Closely): - Concurrent administration with other inactivated vaccines: monitor for increased reactogenicity. - Use of systemic corticosteroids: may attenuate antibody production. - Severe febrile illness at the time of vaccination: postpone dose.